Substance
ID:183511
Names and Identifiers
IUPAC Traditional name
sodium 5-[(3E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-hexahydrocyclopenta[b]furan-3-ylidene]pentanoate
IUPAC name
sodium 5-[(3E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-hexahydro-2H-cyclopenta[b]furan-3-ylidene]pentanoate
Synonyms
(5Z,9α,11α,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid sodium saltProstaglandin I2 sodium saltPGI2-NaProstacyclin sodium saltEpoprostenol 钠
Registration numbers
CAS Number
MDL Number
EC Number
PubChem SID
Beilstein Number
Properties
Safety Information
GHS Precautionary statements
P280
German water hazard class
3
Risk Statements
20/21/22
GHS Hazard statements
H302-H312-H332
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
GHS Pictograms
Acute toxicity (oral, dermal, inhalation), category 4
Skin irritation, category 2
Eye irritation, category 2
Skin sensitisation, category 1
Specific Target Organ Toxicity – Single exposure, category 3
Storage Temperature
-20°C
Safety Statements
22-26-36
GHS Signal Word
Warning
European Hazard Symbols
Harmful (Xn)Physical Property
Solubility
H2O: soluble1 mg/mL (Hydrolyzes to 6-ketoprostaglandin F1α in aqueous solution.)
ethanol: soluble50 mg/mL
Apperance
white to off-white powder
Product Information
Purity
≥96% (HPLC)
Biological Source
synthetic
Molecule Details
Biochem/physiol Actions
Prostacyclin is a short-lived product of the cyclooxygenase pathway in vascular endothelial cells. It is a potent inhibitor of platelet aggregation by antagonizing thromboxane A2 and stimulating platelet adenylyl cyclase.1 Nitric oxide is also produced in vascular endothelium where it inhibits platelet aggregation, regulates inducible cyclooxygenase production, and may work synergistically with prostacyclin to attenuate the thrombotic process. Prostacyclin is vasoprotective, protecting arterial walls from injury-induced lesions and cytoprotective in the liver and gastrointestinal tract.
Prostacyclin therapy improves hemodynamics in pulmonary arterial hypertension.
Prostacyclin is a short-lived product of the cyclooxygenase pathway in vascular endothelial cells. It is a potent inhibitor of platelet aggregation by antagonizing thromboxane A2 and stimulating platelet adenylyl cyclase.1 Nitric oxide is also produced in vascular endothelium where it inhibits platelet aggregation, regulates inducible cyclooxygenase production, and may work synergistically with prostacyclin to attenuate the thrombotic process. Prostacyclin is vasoprotective, protecting arterial walls from injury-induced lesions and cytoprotective in the liver and gastrointestinal tract.
Prostacyclin therapy improves hemodynamics in pulmonary arterial hypertension.
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data